Trials / Recruiting
RecruitingNCT06739122
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 mg and 4.5 mg in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 55 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 10 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dulaglutide | Administered SC |
Timeline
- Start date
- 2025-01-10
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
- First posted
- 2024-12-18
- Last updated
- 2026-03-27
Locations
51 sites across 3 countries: United States, Argentina, Mexico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06739122. Inclusion in this directory is not an endorsement.